Major Depressive Disorder (MDD) 
Trial Solutions

Enhancing study success with advanced clinical research technologies and expert solutions for MDD trials.

Effective solutions for advancing MDD research

Major Depressive Disorder (MDD) is a leading cause of patient suffering and disability around the world. Despite the compelling, unmet need for new and more effective treatments, the development process remains challenging. At Signant, we offer study sponsors a team with the scientific expertise and global experience, as well as innovative technology, to help run successful MDD trials. Leverage our Signant SmartSignals suite to help your adult or pediatric MDD trial succeed.

MDD-1

Why Signant Health

  • Manage Rater Quality to Improve Data Reliability
  • Ensure Participant Comprehension
  • Monitor Study Data as They Flow In
  • Maximize Signal Detection Opportunities
  • Simplify Assessments & Adherence for Participants
  • Digitize Studies for End-to-end Accuracy & Visibility
  • Manage Rater Quality to Improve Data Reliability

    Manage Rater Quality to Improve Data Reliability

    Train and monitor raters to ensure consistency and accuracy with Rater Training and Qualification as well as Central Review services. Our experts ensure raters adhere to eligibility criteria and score diagnostic/efficacy measures correctly, and can help mitigate excessive placebo response to improve your MDD study’s data reliability.
     

  • Ensure Participant Comprehension

    Ensure Participant Comprehension

    Signant’s robust eConsent platform employs multimedia, managed interactions, content flagging, and virtual visits to ensure participant comprehension of your protocol requirements while improving site and participant experience. Automated version control ensures the presentation of the most recently approved ICD versions, thus preventing a common FDA audit finding.

  • Monitor Study Data as They Flow In

    Monitor Study Data as They Flow In

    With its powerful algorithms and support from our team of experts, Signant’s Blinded Data Analytics solution improves clinical data accuracy and reliability throughout the drug development cycle. Our clinical scientists and operations experts analyze study data at all relevant levels and make recommendations for appropriate interventions.

  • Maximize Signal Detection Opportunities

    Maximize Signal Detection Opportunities

    Talk through your MDD protocol with our science and medicine experts, who serve as an extension of your study team. We guide the selection and acquisition of endpoints and assessments, advise on inclusion/
    exclusion criteria, and recommend methods to decrease site and participant burdens while improving data quality.

  • Simplify Assessments & Adherence for Participants

    Simplify Assessments & Adherence for Participants

    Patient-reported and clinician-reported outcome assessments are vital to fully evaluate MDD treatment risk-benefit profiles. Our eCOA solution can be tailored to sites' and patient's needs – guided assessments and built-in edit checks reduce COA errors, while alerts and reminders help improve adherence to medication dosing schedules.

  • Digitize Studies for End-to-end Accuracy & Visibility

    Digitize Studies for End-to-end Accuracy and Visibility

    While all of our solutions can be applied individually, when combined they enhance the data accuracy and operational efficiency of your MDD study. Gain immediate access to electronic data for faster decision-making and improved regulatory inspections.

     

Comprehensive MDD Experience

0

STUDIES

0

PATIENTS

0

COUNTRIES

0

SITES

Explore our MDD trial resources
SOLUTION BROCHURE

MDD Trial Solutions Overview



GET INSIGHTS
VIDEO

MDD Trial Solutions



WATCH [2 MIN]
ARTICLE

Adjunctive Cariprazine for the Treatment of Patients
With Major Depressive Disorder

READ ARTICLE

Ready to learn more?

Discover how Signant can support your current or upcoming MDD trials.